Revision Bulletin
Official: March 1, 2021

Metformin Hydrochloride Extended-Release Tablets

DEFINITION

Metformin Hydrochloride Extended-Release Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of metformin hydrochloride ($C_4H_{11}N_5 \cdot HCl$).

IDENTIFICATION

• **A.** The retention time of the major peak from the *Sample solution* corresponds to that from the *Standard solution*, as obtained in the *Assay*.

ASSAY

• **Procedure**

Buffer solution: 0.5 g/L of sodium 1-heptanesulfonate and 0.5 g/L of sodium chloride in water. Before final dilution, adjust with 0.06 M phosphoric acid to a pH of 3.85.

Mobile phase: Acetonitrile and *Buffer solution* (1:9). [Note—To improve the separation, the composition of acetonitrile and *Buffer solution* may be changed to 1:19, if necessary.]

Diluent: 1.25% solution of acetonitrile in water

Standard solution: (*L*/4000) mg/mL of USP Metformin Hydrochloride RS in *Diluent*, where *L* is the labeled quantity, in mg, of metformin hydrochloride in each Tablet

System suitability stock solution: 12.5 µg/mL each of USP Metformin Related Compound B RS and USP Metformin Related Compound C RS in *Diluent*

System suitability solution: Dilute 0.5 mL of the *System suitability stock solution* with the *Standard solution* to 50 mL.

Sample stock solution: Finely powder NLT 10 Tablets. Transfer powder, equivalent to the average Tablet weight, to a homogenization vessel, and add 500 mL of a 10% acetonitrile solution. Alternately, homogenize and allow to soak until the sample is fully homogenized. [Note—A suggested homogenization sequence is as follows. Homogenize the sample using five pulses, each of 5 s, at about 20,000 rpm, and allow to soak for 2 min. Repeat these steps two additional times.]

Sample solution: Pass a portion of the *Sample stock solution* through a suitable filter of 0.45-µm pore size, discarding the first 3 mL of filtrate. Transfer 25 mL of the filtrate to a 200-mL volumetric flask, and dilute with water to volume.

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 218 nm

Column: 3.9-mm × 30-cm; 10-µm packing L1

Column temperature: 30°

Flow rate: 1 mL/min

Injection volume: 10 µL

Run time: Until after the elution locus of metformin related compound C

System suitability

Sample: *System suitability solution*

[Note—The relative retention times for metformin related compound B, metformin, and metformin related compound C are 0.86, 1.0, and 2.1–2.3, respectively. Metformin related compound C can have a variable retention time. The composition of the *Mobile phase* may be changed to 1:19, if it elutes at a relative retention time of less than 2.1.]

Suitability requirements

Resolution: NLT 1.5 between the peaks due to metformin related compound B and metformin

Tailing factor: NLT 0.8 and NMT 2.0 for the metformin peak

Relative standard deviation: NMT 1.5% for the metformin peak and NMT 10% for each of the peaks due to metformin related compound B and metformin related compound C

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of metformin hydrochloride ($C_4H_{11}N_5 \cdot HCl$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$